Standard BioTools Inc LAB.OQ LAB.O is expected to show a fall in quarterly revenue when it reports results on May 6 for the period ending March 31 2025
The South San Francisco California-based company is expected to report a 11.9% decrease in revenue to $40.1 million from $45.54 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Standard BioTools Inc is for a loss of 7 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Standard BioTools Inc is $2.38, above its last closing price of $1.11.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.06 | -0.07 | -0.09 | Missed | -28.6 |
Sep. 30 2024 | -0.09 | -0.09 | -0.07 | Beat | 22.2 |
Jun. 30 2024 | -0.09 | -0.08 | -0.12 | Missed | -41.2 |
Mar. 31 2024 | -0.13 | -0.11 | -0.27 | Missed | -138.2 |
Dec. 31 2023 | -0.13 | -0.25 | Missed | -92.3 | |
Sep. 30 2023 | -0.12 | -0.12 | -0.27 | Missed | -125 |
Jun. 30 2023 | -0.21 | -0.21 | -0.22 | Missed | -4.8 |
This summary was machine generated May 2 at 21:39 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)